Based on the provided data and recent earnings report, I'll analyze if MOH is overvalued.
Valuation Analysis
MOH's forward P/E of 14.24 for Q4 2024 is significantly lower than previous quarters, showing improving valuation metrics.
Recent Performance
The company projects 9% revenue growth to $42B in 2025, with adjusted EPS guidance of $24.50, representing an 8% year-over-year increase.
Market Sentiment
Recent analyst actions show mixed sentiment. UBS and Barclays maintained Hold ratings with price targets of $305 and $339 respectively, while Truist Securities maintains a Strong Buy with a $370 target.
Conclusion
MOH is not overvalued based on its declining forward P/E ratio, strong revenue growth projections, and analyst price targets indicating 19-24% upside potential. The stock's current valuation appears attractive given its growth trajectory and market position in managed healthcare services.